These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21513501)

  • 21. Protein kinases as targets for cancer treatment.
    Giamas G; Stebbing J; Vorgias CE; Knippschild U
    Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The mitogen-activated protein kinase pathway for molecular-targeted cancer treatment.
    Sebolt-Leopold JS; Herrera R; Ohren JF
    Recent Results Cancer Res; 2007; 172():155-67. PubMed ID: 17607940
    [No Abstract]   [Full Text] [Related]  

  • 23. Promises and drawbacks of targeting cell cycle kinases in cancer.
    Pentimalli F; Giordano A
    Discov Med; 2009 Dec; 8(43):177-80. PubMed ID: 20040266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.
    Dar AC; Shokat KM
    Annu Rev Biochem; 2011; 80():769-95. PubMed ID: 21548788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Kinase inhibitors and their resistance].
    Togashi Y; Nishio K
    Nihon Rinsho; 2015 Aug; 73(8):1323-9. PubMed ID: 26281685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinase inhibitors: narrowing down the real targets.
    Daub H
    Nat Chem Biol; 2010 Apr; 6(4):249-50. PubMed ID: 20300093
    [No Abstract]   [Full Text] [Related]  

  • 27. Protein kinase inhibitors: breakthrough medicines and the next generation.
    Sawyer TK; Wu JC; Sawyer JR; English JM
    Expert Opin Investig Drugs; 2013 Jun; 22(6):675-8. PubMed ID: 23705633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmodium kinases as targets for new-generation antimalarials.
    Lucet IS; Tobin A; Drewry D; Wilks AF; Doerig C
    Future Med Chem; 2012 Dec; 4(18):2295-310. PubMed ID: 23234552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy.
    Soltan OM; Shoman ME; Abdel-Aziz SA; Narumi A; Konno H; Abdel-Aziz M
    Eur J Med Chem; 2021 Dec; 225():113768. PubMed ID: 34450497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer drug development. Preface.
    Sawyers CL; Mellinghoff IK
    Curr Top Microbiol Immunol; 2012; 355():v-vi. PubMed ID: 23227490
    [No Abstract]   [Full Text] [Related]  

  • 31. Focus issue: choreographing the dance of the mitotic kinases.
    Gough NR
    Sci Signal; 2011 Jun; 4(179):eg5. PubMed ID: 21712543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein kinases: Role of their dysregulation in carcinogenesis, identification and inhibition.
    Sarkar N; Singh A; Kumar P; Kaushik M
    Drug Res (Stuttg); 2023 Apr; 73(4):189-199. PubMed ID: 36822216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospects for pharmacological targeting of pseudokinases.
    Kung JE; Jura N
    Nat Rev Drug Discov; 2019 Jul; 18(7):501-526. PubMed ID: 30850748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MAP kinase-interacting kinases--emerging targets against cancer.
    Diab S; Kumarasiri M; Yu M; Teo T; Proud C; Milne R; Wang S
    Chem Biol; 2014 Apr; 21(4):441-452. PubMed ID: 24613018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Introduction for the special issue on kinase inhibitors.
    Galons H
    Eur J Med Chem; 2013 Mar; 61():1. PubMed ID: 23267562
    [No Abstract]   [Full Text] [Related]  

  • 36. Multi-kinase inhibitors, AURKs and cancer.
    Cicenas J; Cicenas E
    Med Oncol; 2016 May; 33(5):43. PubMed ID: 27038473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.
    Finlay MR; Griffin RJ
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5352-9. PubMed ID: 22835870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aurora A Kinase Is a Priority Pharmaceutical Target for the Treatment of Cancers.
    Damodaran AP; Vaufrey L; Gavard O; Prigent C
    Trends Pharmacol Sci; 2017 Aug; 38(8):687-700. PubMed ID: 28601256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting cell cycle kinases for cancer therapy.
    de Cárcer G; Pérez de Castro I; Malumbres M
    Curr Med Chem; 2007; 14(9):969-85. PubMed ID: 17439397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-kinase targets of protein kinase inhibitors.
    Munoz L
    Nat Rev Drug Discov; 2017 Jun; 16(6):424-440. PubMed ID: 28280261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.